Our Lab at Notre Dame Receives Notice of Allowance for Novel Nanoparticle Immunotherapy Technology

The patent office has officially issued a Notice of Allowance for Application US 18/547,664, marking a significant step forward in the fight against cancer. The technology, developed by Prakash Nallathamby and the research team, introduces a novel approach utilizing “Bispecific bridge nanoparticles.”

Bridging the Gap in Cancer Treatment Current challenges in cancer therapy often revolve around targeting mechanisms. This newly allowed patent protects a method that utilizes nanoparticles to serve as a “bridge,” facilitating efficient targeting for:

1. Universal CAR-T Cell Therapy: Allowing T-cells to recognize and attack cancer cells more universally.
2. Targeted Chemotherapy: Improving the precision of drug delivery.

Next Steps The University of Notre Dame’s IDEA Center, led by Intellectual Property Manager Carrie Jennings, is finalizing the administrative steps, with the official patent expected to issue shortly after April 20th.

This allowance validates the novelty of the team’s work and paves the way for commercialization and future clinical applications.

Science #CancerCure #NotreDame #Biotech #Patented